Skip to main content
OpenTrials
Completed

NCT Number: NCT01743053

A Pilot Trial of the Use of ReCell® Autologous Cell Harvesting Device for Venous Leg Ulcers

This is a prospective, randomised, open label, controlled pilot study to evaluate the safety and preliminary effectiveness of the ReCell Autologous Cell Harvesting Device (ReCell) for the management of chronic leg ulcers associated with venous insufficiency. Outcome will be compared between study participants receiving standard care (debridement, compression therapy) and participants receiving ReCell in addition to standard care.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Hôpital Lapeyronie, Montpellier, France

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Chronic venous leg ulcer (CEAP Clinical classification of 6)
  • Confirmed, actively managed venous reflux
  • No exposed tendon or bone
  • Ulcer is >4 weeks in duration
  • Ulcer surface area between 2cm2 and 80cm2
  • ABI ≥ 0.8
  • The patient is 18 years of age or older
  • The patient is willing to complete all follow-up evaluations required by the study protocol
  • The patient is able to abstain from any other treatment of the ulcer for the duration of the study, unless medically necessary
  • The patient agrees to abstain from enrolment in any other clinical trial for the duration of the study
  • The patient is able to read and understand instructions and give voluntary written informed consent
  • The patient is able and willing to follow the protocol requirements (including compression therapy)
  • Patients enrolling at any site in France must have an affiliation to a social security scheme

Exclusion criteria

  • Study treatment area has exposed bone or tendon
  • Poorly controlled diabetes
  • Arterial insufficiency (ABI < 0.8)
  • Pregnant/lactating females (self-reported or tested, per institutional requirements)
  • The patient has an active wound infection requiring antibiotic therapy
  • The patient has had a prior surgical treatment of the ulcer within the past 60 days
  • The patient has a life expectancy of 1-year or less
  • The patient has a severe dermatological disorder (e.g. severe psoriasis, epidermolysis bullosa, pyoderma gangrenosum).
  • The patient is unable to follow the protocol
  • The patient is taking, or has taken in the past 60 days, mycophenolate mofetil or >10mg of corticosteroids per day.
  • The patient has other concurrent conditions that in the opinion of the investigator may compromise patient safety or study objectives
  • The patient has a known hypersensitivity to trypsin or Compound Sodium Lactate for Irrigation (Hartmann's) solution.
  • The patient is a vulnerable or protected adult.
  • The patient is unable to provide consent

Treatment and study plan

Standard Care plus ReCell

Device

Standard care

Other

Primary outcomes

  1. Wound healing

    Time frame: 12 weeks

    The primary objective of the study is to assess the difference in incidence of ulcer closure (investigator assessed as complete epithelialisation without drainage) between the ReCell group and the control group.

Secondary outcomes

  1. Wounds characterization/Quality of Life

    Time frame: At each follow-up visit (1, 2, 4, 6, 8, 12, 24, 52 weeks)

    • Wound area
    • Wound volume
    • Pain
    • Recurrence
    • Health-related Quality of Life
  2. Dressing Change

    Time frame: At each follow-up visit (1, 2, 4, 6, 8, 12, 24, 52 weeks) until healed

    • Dressing change

Sponsors and collaborators

Lead sponsor

Avita Medical

Industry

Collaborators

  • NAMSA

Registry information

Important dates

Study start
2013
Primary completion
2015
Study completion
2015
First posted
Dec 6, 2012
Registry last updated
Jun 8, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.